{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:30Z","timestamp":1753868670734,"version":"3.41.2"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Therapy\u2010related leukemia is a well\u2010recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>Hematologic toxicities including late\u2010onset myeloid neoplasms have been reported after PRRT; however, therapy\u2010related chronic myeloid leukemia (TR\u2010CML) following PRRT is a relatively rare entity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We present a 64\u2010year\u2010old male who received PRRT for pancreas neuroendocrine tumor and then developed TR\u2010CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with TR\u2010CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The physicians should be aware of the short\u2010 and long\u2010term hematologic toxicities of PRRT including TR\u2010CML, and careful monitoring is mandatory in this group of patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1282","type":"journal-article","created":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T07:11:26Z","timestamp":1601190686000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapy\u2010related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor"],"prefix":"10.1002","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-3388","authenticated-orcid":false,"given":"Selin","family":"Kucukyurt","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6983-8504","authenticated-orcid":false,"given":"Yeliz","family":"Yagiz Ozogul","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cerrahpasa Faculty of Medicine Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-5773","authenticated-orcid":false,"given":"Abdulkadir","family":"Ercaliskan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-1972","authenticated-orcid":false,"given":"Levent","family":"Kabasakal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cerrahpasa Faculty of Medicine Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine Istanbul University\u2010Cerrahpasa  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441409"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1002-4"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809058378"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1748"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.01.003"},{"key":"e_1_2_9_8_1","first-page":"1","article-title":"Therapy related chronic myeloid Leukemia (trCML) or non\u2010 therapy related second malignancy chronic myeloid Leukemia (smCML) following diffuse large B\u2010cell lymphoma (DLBCL): a case report and review of literature","volume":"4","author":"Louis R","year":"2016","journal-title":"Am J Med Case Rep"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0078"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000874"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31408"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.189712"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3945-z"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14336"},{"issue":"5","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"L17\u2010L23","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu\u2010octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau B","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-792143"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:52:46Z","timestamp":1693810366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/cnr2.1282"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1282","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"2020-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1282"}}